Jefferies has downgraded Amicus Therapeutics to 'Buy' from 'Hold' and trimmed its price target to $14.50, aligning it with BioMarin's pending $4.8 billion acquisition offer. The move reflects analyst skepticism about competing bids emerging for the rare disease biotech firm.
Quince Therapeutics' lead candidate, eDSP, has failed to meet primary and secondary endpoints in its pivotal Phase III NEAT trial for the rare neurological disorder Ataxia-Telangiectasia (A-T), triggering a catastrophic drop in the company's share price.
A 12-foot great white shark, tracked from Nova Scotia, has been detected in the Mississippi Sound, marking an unusual westward migration into the Gulf and offering clues about the region's marine health.
With consumer staples out of favor and a yield surpassing the S&P 500, Coca-Cola's resilient business and decades of dividend growth present a compelling case for long-term investors.
The new campus in McBee, SC, aims to bolster North American supply chains for critical minerals, starting with a 2,000-ton annual processing capacity for magnet scrap.
Roth Capital has upgraded Energy Fuels (UUUU) from 'Sell' to 'Neutral', raising its price target to $15. The move follows the uranium miner's strategic acquisition of Australian Strategic Materials, expanding its rare earths portfolio and positioning within Western critical mineral supply chains.
Despite a new U.S. framework for involvement, extracting Greenland's rare earth metals is hampered by Arctic extremes, local political opposition, and strained transatlantic ties.
Analyst sell ratings are rare on Wall Street, making them noteworthy when they appear. We examine one such case where pessimism may have gone too far, creating a potential opportunity, alongside two stocks where the cautious outlook appears justified.
Charter Communications shares surged Friday after the cable giant reported a rare quarterly gain in pay-TV subscribers, a bright spot amid ongoing broadband pressures. The company's strategy of bundling streaming services appears to be resonating with customers.
Eli Lilly bolsters its long-term growth strategy through two new R&D partnerships and a key regulatory milestone for an ovarian cancer drug, signaling a strategic push beyond its blockbuster diabetes and obesity treatments.
Damascus residents face electricity bills exceeding their monthly incomes after a massive government price hike, sparking rare public protests and deepening the crisis for a war-weary population.
From economic despair to demands for fundamental rights, Iran's recent wave of protests revealed a rare, broad-based defiance. Through the eyes of those who were there, a story emerges of fleeting hope shattered by a security response activists call the deadliest in decades.
Bank of America has upgraded Apellis Pharmaceuticals (APLS) to 'Buy,' citing robust early adoption of its drug Empaveli and significant undervaluation of its potential in treating rare kidney diseases, despite a more cautious outlook from Wells Fargo.
SpaceX is reportedly targeting June 2026 for its long-awaited public market debut, with sources suggesting the timing could be synchronized with a rare planetary alignment and CEO Elon Musk's 55th birthday, as the company seeks capital for its ambitious Mars missions.
From delivering pizzas to building a global sportswear empire, Ben Francis's journey to a $1.4 billion net worth is a modern business fable. Yet, in a candid podcast interview, the Gymshark CEO argues that equating self-worth with wealth is a 'wildly unproductive way to live,' offering a rare glimpse into the mindset behind the paper fortune.
MarketAxess Holdings (MKTX), once a high-flying fintech darling, has seen its share price erode by nearly 70% over five years. As the bond trading platform grapples with shifting market dynamics and increased competition, investors are left debating whether the current valuation presents a rare buying opportunity or signals deeper structural challenges.
Digital asset funds have recorded a second consecutive week of massive outflows, totaling $1.7 billion, as hawkish Fed signals and geopolitical tensions trigger a defensive shift. While Bitcoin and Ethereum led the retreat, tokenized precious metals emerged as a rare destination for new capital.
Shares of specialty insurer Kinsale Capital have tumbled over 11% in six months, starkly underperforming the surging S&P 500. As investors digest its latest earnings, the debate intensifies: Is this a rare chance to buy a high-growth company at a discount, or a signal of deeper challenges ahead?
In a rare break from Wall Street's typically optimistic consensus, a handful of prominent stocks are receiving bearish price targets that signal deep-seated concerns. We examine the challenges facing Deckers, MSC Industrial, and Guardant Health, and why investors might want to look elsewhere.
Harmony Biosciences CFO Sandip Kapadia has liquidated his entire direct stake in the company, a move that contrasts sharply with the firm's robust financial performance and bullish $1 billion revenue target for its flagship drug WAKIX by 2026. While the sales were pre-planned, the timing fuels debate on insider confidence versus corporate optimism.
